Abstract
Oestrogen receptor (ER) content gives a direct indication of the chances that a breast cancer patient will show a sustained response to endocrine therapy. Thus, an ER value should be recorded for every breast cancer patient. ER was traditionally measured by a ligand binding assay (LBA). LBA is not suitable for all routine hospitals in which breast cancer is treated. More appropriate is immunohistochemistry (IHC). This paper identifies advantages and disadvantages of both assays, suggests that both methods predict equally response to endocrine therapies and describes a simple, semi-quantitative IHC for which external quality assurance works successfully.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
